Compare Quest Diagnostics Inc (DGX) vs AT&T Inc. (T) Price & Performance

Quest Diagnostics (DGX) trades at $227.00, down 0.64% on the day, with the stock showing strong fundamental performance including three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.04B in 2025. Technical indicators signal bearish momentum with the current price near key support at $226, while the company maintains solid profitability with 9.19% net income margin and 14.35% ROE. Recent developments include positive clinical study results and a new partnership with Apple Health app for lab testing integration.

The investment outlook remains positive with analyst consensus target of $250 representing 10% upside potential, though Medicare reimbursement cuts pose near-term headwinds. Growth drivers include advanced diagnostics expansion and consumer testing demand, balanced against technical weakness and regulatory uncertainty. The stock offers value with reasonable P/E of 24.1 and consistent dividend payments.

AT&T (T) trades at $24.475, up 0.2% on the day, with a bearish technical signal but strong fundamentals including a low P/E of 8.08 and robust profitability. Recent earnings have consistently beaten estimates, and the company maintains a solid dividend. Cash flow improved significantly in 2025 to $15.12B net, while debt levels remain manageable. News highlights a $3B fiber deal with Corning and joint ventures to expand coverage.

The stock appears undervalued with a consensus price target of $27.61, offering a 13% upside. Key opportunities include fiber expansion and wireless growth, but risks involve intense competition, high debt, and potential dividend sustainability concerns. Analyst sentiment is mixed with 44% buy ratings, suggesting cautious optimism for long-term income investors.